Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Despite Ozempic being the most recognisable brand name, as far as the people prescribing it are concerned weight loss is ...

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be presented at ECO 2025 - covering burden, and the value of treatment and prevention ...

Novo Nordisk’s GLP-1 agonist Ozempic has shown efficacy in yet another indication, achieving a 24% reduction in kidney disease-related events in people with type 2 diabetes and chronic kidney ...

Ozempic is now the only GLP-1 receptor agonist proven to reduce the risk of chronic kidney disease and people living with type 2 diabetes and chronic kidney disease. Novo Nordisk remains the ...

Nearly twice as many people taking semaglutide stopped their fatty liver disease without further scarring of the organ, ...

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.

Millions of women may be unknowingly living with risk factors for heart, kidney ... disease. The American Heart Association's new CKM health initiative, supported by founding sponsors Novo Nordisk ...

The cutting-edge weight-loss drug Ozempic ... of semaglutide, Novo Nordisk, plans to seek U.S. Food and Drug Administration (FDA) approval for the drug to treat fatty liver disease later this ...

In a statement, a Novo Nordisk spokesperson said the disease is “very rare,” and is not considered an adverse drug reaction to semaglutide drugs such as Ozempic, Wegovy and Rybelsus.

and cardiovascular disease. Also Read: Counterfeit Ozempic Identified in US Supply Chain With Fake Labels And Needles, FDA Alerts The ruling reinforces the FDA’s position that Novo Nordisk’s ...